Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma

This study is ongoing, but not recruiting participants.
Sponsor:
Information provided by (Responsible Party):
Geron Corporation
ClinicalTrials.gov Identifier:
NCT01242930
First received: November 16, 2010
Last updated: July 23, 2013
Last verified: January 2013

November 16, 2010
July 23, 2013
November 2010
December 2013   (final data collection date for primary outcome measure)
Rate of Improvement in Response [ Time Frame: From time of first dose (Cycle 1 day 1) through end of study period (12 mos. after last participant is enrolled) ] [ Designated as safety issue: No ]
To determine the rate of improvement in response in patients with previously treated multiple myeloma following treatment with imetelstat alone or in combination wtih lenalidomide maintenance therapy. Response will be assessed using the International Uniform Response Criteria for Multiple Myeloma (IURCMM).
Objective Response Rate [ Time Frame: From time of first dose (Cycle 1 day 1) through end of study period (12 mos. after last participant is enrolled) ] [ Designated as safety issue: No ]
To determine the rate of objective response (complete, very good partial, or partial response) in patients with previously treated multiple myeloma following treatment with imetelstat. Response will be assessed using the International Uniform Response Criteria for Multiple Myeloma (IURCMM)
Complete list of historical versions of study NCT01242930 on ClinicalTrials.gov Archive Site
  • Progression-free Survival (PFS) [ Time Frame: From time of first dose (Cycle 1 day 1) through end of study (12 mos. after last participant is enrolled) ] [ Designated as safety issue: No ]
    As assessed from Cycle 1 Day 1 to first evidence of PD as defined by IURCMM, or death, whichever occurs first.
  • Safety and Tolerability [ Time Frame: From time of first dose (Cycle 1 day 1) through end of study (12 mos. after last participant is enrolled) ] [ Designated as safety issue: Yes ]

    The safety and tolerability of imetelstat will be assessed by the incidence, nature, relatedness and severity of adverse events, laboratory abnormalities and vital signs.

    Patients who develop Grade 3 or 4 cytopenias (other than lyphophenia and/or leukopenia alon) will receive addiontal safety monitoring for reversibility.

  • Progression-free Survival (PFS) [ Time Frame: From time of first dose (Cycle 1 day 1) through end of study (12 mos. after last participant is enrolled) ] [ Designated as safety issue: No ]
    As assessed from Cycle 1 Day 1 to first evidence of PD as defined by IURCMM, or death, whichever occurs first.
  • Safety and Tolerability: Number of patients with hematological toxicities [ Time Frame: From time of first dose (Cycle 1 day 1) through end of study (12 mos. after last participant is enrolled) ] [ Designated as safety issue: Yes ]

    The safety and tolerability of imetelstat will be assessed by the incidence, nature, relatedness and severity of adverse events, laboratory abnormalities and vital signs.

    Patients who develop Grade 3 or 4 cytopenias (other than lyphophenia and/or leukopenia alon) will receive addiontal safety monitoring for reversibility.

Not Provided
Not Provided
 
Open Label Study With Imetelstat to Determine Effect of Imetelstat in Patients w/ Previously Treated Multiple Myeloma
A Phase II Trial to Determine the Effect of Imetelstat (GRN163L) on Patients With Previously Treated Multiple Myeloma

This is an open label Phase II study to determine the rate of improvement in response of patients with previously treated multiple myeloma to imetelstat alone or in combination with lenalidomide maintenance therapy. This study will include multiple myeloma patients who either have achieved disease stabilization or who have achieved at least a partial response (PR) but failed to achieve a complete response (CR) after cytoreductive therapy for multiple myeloma; ie, have detectable but non-progressing disease and will most likely relapse.

Not Provided
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Multiple Myeloma
Drug: Standard of Care
Standard of Care
Experimental: Imetelstat plus standard of care
9.4 mg/kg over a 2 hour IV Infusion on Day 1 and Day 8 of a 28-day cycle.
Intervention: Drug: Standard of Care
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
48
December 2013
December 2013   (final data collection date for primary outcome measure)

Inclusion Criteria:

Willing and able to sign an informed consent Male or female, 18 years or older Confirmed diagnosis of multiple myeloma (secretory disease) by International Myeloma Working Group Diagnostic Criteria

Patients must meet one of the following criteria:

o Previously treated patients with multiple myeloma who achieved at least stable disease but who have failed to achieve a complete response (CR) after a minimum of one cytoreductive therapy for multiple myeloma and have detectable but non-progressing disease. Patients must have received at least one proteasome inhibitor (eg, bortezomib) or one immunomodulatory agent (eg, thalidomide or lenalidomide) or both.

Patients receiving lenalidomide as maintenance therapy may continue to receive this therapy provided that the patient has been on this maintenance therapy for a minimum of 3 months and has evidence of disease stabilization.

Disease stabilization will be defined as an M protein that varies ≤ 25% over the three measurements or remains under 0.5 g/dL whichever is smaller.

ECOG performance status 0-2 Life expectancy ≥ 3 months

Laboratory criteria (within 14 days of first study drug administration):

  • ANC ≥ 1000/μL
  • Platelet count ≥ 50 x 103/μL (without transfusion support within 2 weeks prior to first study drug administration)
  • Hemoglobin ≥ 8.0 g/dL
  • Serum creatinine ≤ 3 x the upper limit of normal (ULN)
  • AST (SGOT) and ALT (SGPT) ≤ 2.5 x the upper limit of normal (ULN), unless due to disease.

Must have fully recovered from any previous cancer treatments and/or major surgery.

Women of childbearing potential must have a negative serum pregnancy test and agree to use effective birth control (two reliable forms of contraception) during and for at least 12 weeks after the last treatment.

Males must agree to use effective birth control for themselves or their partner during and for 12 weeks after the last treatment with imetelstat. For those patients receiving lenolidomide, males must use latex condom during sexual contact with women of childbearing potential even if they have undergone a successful vasectomy.

Exclusion Criteria:

Women who are pregnant or breast feeding Prior radioimmunotherapy. Known intracranial disease or epidural disease. Patients with lytic lesions of the cranium or spine secondary to myeloma are eligible to enroll.

Clinically significant cardiovascular disease or condition including:

  • Congestive heart failure (CHF) requiring therapy
  • Need for antiarrhythmic therapy for a ventricular arrhythmia
  • Severe conduction disturbance
  • Angina pectoris requiring therapy
  • Uncontrolled hypertension per the Investigator's discretion
  • New York Heart Association Class II, III, or IV cardiovascular disease Active or chronically recurrent bleeding (eg, active peptic ulcer disease) Clinically relevant active infection. Serious co-morbid medical conditions, including cirrhosis and chronic obstructive or chronic restrictive pulmonary disease.

Symptomatic hyperviscosity syndrome. Any other cancer therapy including chemotherapy, monoclonal antibody, signal transduction inhibitor, immunotherapy, glucocorticoid (except topical or as premedication), thalidomide within 3 weeks prior to first study drug administration.

Investigational therapy within 4 weeks prior to first study drug administration.

Major surgery within 4 weeks prior to first study drug administration (central line placement is allowed) Anti-platelet therapy within 2 weeks prior to first study drug administration, other than low dose aspirin prophylaxis therapy.

Full dose anticoagulation. Prophylactic low dose administration for management of IV access devices is allowed.

Known positive serology for human immunodeficiency virus (HIV. Any other severe, acute, or chronic medical or psychiatric condition, laboratory abnormality, or difficulty complying with protocol requirements that may increase the risk associated with study participation or study drug administration or may interfere with the interpretation of study results and, in the judgment of the investigator, would make the patient inappropriate for this study

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT01242930
CP14B013
No
Geron Corporation
Geron Corporation
Not Provided
Study Director: Ted Shih, PharmD Geron Corporation
Principal Investigator: Carol Ann Huff, M.D. Sidney Kimmel Cancer Center at Johns Hopkins Hospital
Geron Corporation
January 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP